Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ixazomib

ixazomib

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of ixazomib

49 trials tracked of ixazomib: 7 in phase 3 or 4 and 4 with published results. The most-cited published study has 235 citations.

49Trials tracked
7Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 4 1 Phase 3 6 Phase 2 29 Phase 1 11 Other / NA 2
  1. Phase 3 A Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Participants With Multiple Myeloma Following Autologous Stem Cell Transplant Completed · 235 cited
  2. Phase 3 IXAZOMIB Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Patients With Newly Diagnosed Multiple Myeloma Completed · 97 cited
  3. Phase 3 A Study of Oral Ixazomib Maintenance Therapy in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Not Treated With Stem Cell Transplantation (SCT) Completed · 78 cited
  4. Phase 4 A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy Completed · 2 cited
  5. Phase 3 Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial Completed
  6. Phase 3 Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Participants With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (SCT) Completed
Show 43 more trials
  1. Phase 3 A Phase 3 Study Comparing Oral Ixazomib Plus Lenalidomide and Dexamethasone Versus Placebo Plus Lenalidomide and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma Completed
  2. Phase 2 Ixazomib With Cyclophosphamide and Dexamethasone in Patients With Previously Untreated Symptomatic Multiple Myeloma or Light Chain Amyloidosis Completed
  3. Phase 2 Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Completed
  4. Phase 2 A Study of Ixazomib and Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma Completed
  5. Phase 2 Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia Completed
  6. Phase 2 Ixazomib Citrate, Pomalidomide, Dexamethasone, Stem Cell Transplant in Treating Relapsed or Refractory Multiple Myeloma Completed
  7. Phase 2 Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma Completed
  8. Phase 2 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM) Completed
  9. Phase 2 A Study of Ixazomib, Given With Dexamethasone in Adults With Multiple Myeloma Completed
  10. Phase 2 Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma Completed
  11. Phase 2 Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib Completed
  12. Phase 2 Ixazomib Plus Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Completed
  13. Phase 2 Ixazomib Citrate and Lenalidomide After Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  14. Phase 2 Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma Completed
  15. Phase 2 Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302) Completed
  16. Phase 2 Ixazomib Rollover Study Completed
  17. Phase 2 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma Completed
  18. Phase 2 Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's Macroglobulinemia Completed
  19. Phase 2 Lenalidomide With or Without Ixazomib Citrate and Dexamethasone in Treating Patients With Residual Multiple Myeloma After Donor Stem Cell Transplant Completed
  20. Phase 2 Study of Ixazomib to Prevent Recurrent or Late Acute and Chronic Graft-versus-Host Disease 1-year After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies Completed
  21. Phase 2 UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Completed
  22. Phase 2 Ixazomib, Cyclophosphamide and Dexamethasone for Multiple Myeloma Completed
  23. Phase 2 Ixazomib and Dexamethasone Versus Ixazomib, Dexamethasone and Lenalidomide, Randomized With NFKB2 Rearrangement Completed
  24. Phase 2 Phase 2 Study to Evaluate the Oral Combination of Ixazomib (MLN9708) With Cyclophosphamide and Dexamethasone in Patients With Newly Diagnosed or Relapsed and/or Refractory Multiple Myeloma Completed
  25. Phase 2 Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma Completed
  26. Phase 2 A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma Completed
  27. Phase 2 Ixazomib Citrate in Treating Patients With Chronic Graft-versus-Host Disease Completed
  28. Phase 2 A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Completed
  29. Phase 2 Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma Completed
  30. Phase 2 Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma Completed
  31. Phase 1 Study of Oral Ixazomib in Adult Participants With Relapsed or Refractory Light Chain Amyloidosis Completed
  32. Phase 1 A Study of IXAZOMIB in Adult Patients With Lymphoma Completed
  33. Phase 1 A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies Completed
  34. Phase 1 Phase 0 Analysis of Ixazomib (MLN9708) in Patients With Glioblastoma Completed
  35. Phase 1 Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Completed
  36. Phase 1 Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma Completed
  37. Phase 1 Mass Balance, Pharmacokinetics and Metabolism Study of IXAZOMIB Completed
  38. Phase 1 Pharmacokinetic Study of Oral IXAZOMIB in Cancer Patients With Liver Dysfunction Completed
  39. Phase 1 Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to Treatment Completed
  40. Phase 1 Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Participants With Normal Renal Function or Severe Renal Impairment Completed
  41. Phase 1 Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma Completed
  42. N/A A Study in Relapsed and/or Refractory Multiple Myeloma Patients Treated With Ixazomib Plus Lenalidomide and Dexamethasone Completed
  43. N/A NINLARO Capsules Drug Use-Results Survey (All-Case Surveillance) "Relapsed/Refractory Multiple Myeloma" Completed

Showing the 49 most-cited and recently-updated of 49 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma
Oncology Sys. Review
Two-Case Report Evaluates Lisaftoclax Plus Ixazomib and Dexamethasone in Relapsed Multiple Myeloma Report reveals disease control in two high-risk myeloma patients
This publication is a case report involving 2 patients with transplant-ineligible relapsed or refractory ultra-high-risk multiple myeloma.
Two patients with ultra-high-risk myeloma achieved durable disease control using a new drug combination after CAR-T therapy.
Frontiers Apr 28, 2026